Patents by Inventor Matthias Eckhardt

Matthias Eckhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors
    Publication number: 20200054617
    Abstract: Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of formula (I) can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: August 14, 2019
    Publication date: February 20, 2020
    Inventors: Matthias ECKHARDT, Andreas GOLLNER, Elke LANGKOPF, Holger WAGNER, Dieter WIEDENMAYER
  • Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
    Patent number: 10550127
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10538490
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Stefan Peters, Holger Wagner
  • Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
    Publication number: 20200017515
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: February 2, 2018
    Publication date: January 16, 2020
    Inventors: Matthias ECKHARDT, Holger WAGNER, Stefan PETERS
  • Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20190389815
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 26, 2019
    Inventors: Matthias ECKHARDT, Holger WAGNER
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20190381037
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 19, 2019
    Inventors: Matthias ECKHARDT, Holger WAGNER
  • Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20190375712
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 12, 2019
    Inventors: Matthias ECKHARDT, Holger WAGNER
  • Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
    Patent number: 10501440
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: December 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Iain Lingard, Dieter Wolfgang Hamprecht, Remko Alexander Bakker, Matthias Eckhardt, Andreas Gollner, Joerg P. Hehn, Elke Langkopf, Holger Wagner, Bernd Wellenzohn, Dieter Wiedenmayer
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20190352266
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Application
    Filed: January 22, 2018
    Publication date: November 21, 2019
    Inventors: Matthias ECKHARDT, Holger WAGNER, Stefan PETERS
  • Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
    Patent number: 10442795
    Abstract: The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 and R3 are defined according to claim 1. Furthermore this inventions relates to intermediates obtained in these processes.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Frank Himmelsbach, Xiao-Jun Wang, Wenjun Tang, Xiufeng Sun, Li Zhang, Dhileepkumar Krishnamurthy, Christopher Hugh Senanayake, Zhengxu Han
  • Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20190241521
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: October 18, 2017
    Publication date: August 8, 2019
    Inventors: Matthias ECKHARDT, Stefan PETERS, Holger WAGNER
  • Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10253004
    Abstract: The present invention relates to compounds of formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 10202383
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier
  • [{[2,3-Dihydro-1H-inden-1-yl]amino}-2H,3H-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
    Publication number: 20180354962
    Abstract: The present invention relates to compounds of general formula I wherein the groups R, R1, R2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: September 5, 2016
    Publication date: December 13, 2018
    Inventors: Matthias ECKHARDT, Holger WAGNER, Stefan PETERS
  • Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Patent number: 10125101
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Holger Wagner, Stefan Peters
  • Heteroarylcarboxamide Derivatives as Plasma Kallikrein Inhibitors
    Publication number: 20180305339
    Abstract: Disclosed are heteroarylcarboxamides of formula (I), and pharmaceutically acceptable salts thereof, wherein A, T, R1, R2 and R3 are as defined herein. Also disclosed are methods of using these compounds for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.
    Type: Application
    Filed: April 16, 2018
    Publication date: October 25, 2018
    Inventors: Sara FRATTINI, Iain LINGARD, Dieter Wolfgang HAMPRECHT, Remko Alexander BAKKER, Matthias ECKHARDT, Andreas GOLLNER, Joerg P. HEHN, Elke LANGKOPF, Holger WAGNER, Bernd WELLENZOHN, Dieter WIEDENMAYER
  • 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180291025
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Roland MAIER
  • Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
    Publication number: 20180208560
    Abstract: The present invention relates to compounds of formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: January 22, 2018
    Publication date: July 26, 2018
    Inventors: Matthias ECKHARDT, Holger WAGNER, Stefan PETERS
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 10023574
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 17, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier
  • INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20180148411
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 21, 2017
    Publication date: May 31, 2018
    Inventors: Matthias ECKHARDT, Holger WAGNER, Stefan PETERS